Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Total Liabilities (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Total Liabilities data on record, last reported at $47.3 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 197.03% year-over-year to $47.3 million; the TTM value through Sep 2025 reached $47.3 million, up 197.03%, while the annual FY2024 figure was $5.7 million, 52.92% down from the prior year.
  • Total Liabilities reached $47.3 million in Q3 2025 per MBRX's latest filing, up from $25.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $47.3 million in Q3 2025 and bottomed at $4.4 million in Q3 2023.
  • Average Total Liabilities over 5 years is $10.8 million, with a median of $7.2 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: tumbled 54.78% in 2021, then surged 262.94% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $5.1 million in 2021, then increased by 2.63% to $5.2 million in 2022, then soared by 132.15% to $12.1 million in 2023, then tumbled by 52.92% to $5.7 million in 2024, then soared by 726.88% to $47.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $47.3 million in Q3 2025, $25.2 million in Q2 2025, and $7.2 million in Q1 2025.